MX367768B - Composiciones que representan un virus de la enfermedad de newcastle atenuado y métodos de uso en el tratamiento de neoplasias. - Google Patents

Composiciones que representan un virus de la enfermedad de newcastle atenuado y métodos de uso en el tratamiento de neoplasias.

Info

Publication number
MX367768B
MX367768B MX2016002771A MX2016002771A MX367768B MX 367768 B MX367768 B MX 367768B MX 2016002771 A MX2016002771 A MX 2016002771A MX 2016002771 A MX2016002771 A MX 2016002771A MX 367768 B MX367768 B MX 367768B
Authority
MX
Mexico
Prior art keywords
methods
disease virus
newcastle disease
treating neoplasia
modified
Prior art date
Application number
MX2016002771A
Other languages
English (en)
Other versions
MX2016002771A (es
Inventor
Jin Hong
Cheng Xing
GALINSKI Mark
MCCOURT Matthew
Carroll Danielle
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2016002771A publication Critical patent/MX2016002771A/es
Publication of MX367768B publication Critical patent/MX367768B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos para inducir la regresión tumoral en sujetos humanos que utilizan una cepa mesogénica modificada del virus de la enfermedad de Newcastle (VEN) con sitio de escisión de la proteína F modificado que es no patogénica para las aves (lentogénica) pero que sí exhibe propiedades oncolíticas. Los métodos descritos proporcionan un medio seguro, eficaz y confiable para inducir la regresión de un tumor en un individuo que lo necesita. Los métodos superan las desventajas de utilizar cepas patogénicas de virus en terapias para seres humanos.
MX2016002771A 2013-09-03 2014-09-02 Composiciones que representan un virus de la enfermedad de newcastle atenuado y métodos de uso en el tratamiento de neoplasias. MX367768B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361873039P 2013-09-03 2013-09-03
PCT/EP2014/068619 WO2015032755A1 (en) 2013-09-03 2014-09-02 Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Publications (2)

Publication Number Publication Date
MX2016002771A MX2016002771A (es) 2016-09-06
MX367768B true MX367768B (es) 2019-09-05

Family

ID=51492938

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002771A MX367768B (es) 2013-09-03 2014-09-02 Composiciones que representan un virus de la enfermedad de newcastle atenuado y métodos de uso en el tratamiento de neoplasias.
MX2019010364A MX2019010364A (es) 2013-09-03 2016-03-02 Composiciones que presentan un virus de la enfermedad de newcastle atenuado y metodos de uso en el tratamiento de neoplasias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010364A MX2019010364A (es) 2013-09-03 2016-03-02 Composiciones que presentan un virus de la enfermedad de newcastle atenuado y metodos de uso en el tratamiento de neoplasias.

Country Status (25)

Country Link
US (2) US10519426B2 (es)
EP (3) EP4101457A1 (es)
JP (2) JP6557234B2 (es)
KR (2) KR102285894B1 (es)
CN (2) CN106163532B (es)
AU (2) AU2014317215C1 (es)
CA (1) CA2922071C (es)
CY (2) CY1121993T1 (es)
DK (2) DK3508209T3 (es)
EA (2) EA202191926A3 (es)
ES (2) ES2708755T3 (es)
HK (1) HK1231393A1 (es)
HR (2) HRP20190250T1 (es)
HU (1) HUE042382T2 (es)
LT (2) LT3041490T (es)
ME (1) ME03345B (es)
MX (2) MX367768B (es)
PL (2) PL3041490T3 (es)
PT (2) PT3508209T (es)
RS (2) RS58332B1 (es)
SI (2) SI3041490T1 (es)
SM (2) SMT202200214T1 (es)
TR (1) TR201902073T4 (es)
TW (1) TWI653334B (es)
WO (1) WO2015032755A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2251034B1 (en) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
CN106163532B (zh) * 2013-09-03 2019-12-31 免疫医疗有限公司 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
EP3288595B1 (en) * 2015-04-28 2020-12-30 The University Of Georgia Research Foundation, Inc. Piv5-based amplifying virus-like particles
KR102762431B1 (ko) 2016-01-08 2025-02-03 레플리뮨 리미티드 변형된 항종양 바이러스
EP3246410A1 (en) 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN108486279A (zh) * 2017-09-21 2018-09-04 山东省农业科学院家禽研究所 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
JP2021530501A (ja) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ 癌の治療のためのａｐｍｖ及びその使用
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
JP2023518295A (ja) * 2020-03-20 2023-04-28 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
CA3161532A1 (en) * 2021-06-03 2022-12-03 University Of Guelph Engineered newcastle disease virus vector and uses thereof
JP2026504603A (ja) * 2023-02-06 2026-02-05 サイアンバック エルエルシー 修飾ｐｉｖ５ワクチンベクター：作製方法及び使用方法
KR20250083186A (ko) * 2023-11-29 2025-06-09 주식회사 카브 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7724558B1 (en) * 1999-03-19 2010-05-25 Nec Corporation Magnetic signal transmission line
AU7607900A (en) * 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
ES2550179T3 (es) * 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
AU2014241843B2 (en) * 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
CN106163532B (zh) * 2013-09-03 2019-12-31 免疫医疗有限公司 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法
CN109099045A (zh) * 2018-10-30 2018-12-28 浙江斯泰新材料科技股份有限公司 防松锁固型螺钉

Also Published As

Publication number Publication date
HK1231393A1 (zh) 2017-12-22
AU2019204419B2 (en) 2021-09-02
RS58332B1 (sr) 2019-03-29
CN106163532A (zh) 2016-11-23
AU2014317215C1 (en) 2019-09-12
WO2015032755A1 (en) 2015-03-12
SI3508209T1 (sl) 2023-01-31
EA201690425A1 (ru) 2016-08-31
LT3508209T (lt) 2022-06-10
PT3041490T (pt) 2019-02-06
SI3041490T1 (sl) 2019-03-29
HRP20190250T1 (hr) 2019-05-31
EA202191926A2 (ru) 2021-10-29
KR20210048605A (ko) 2021-05-03
PL3041490T3 (pl) 2019-05-31
EA202191926A3 (ru) 2022-01-31
ES2708755T3 (es) 2019-04-11
ME03345B (me) 2019-10-20
KR102285894B1 (ko) 2021-08-04
CY1121993T1 (el) 2020-10-14
AU2014317215A1 (en) 2016-04-14
SMT201900094T1 (it) 2019-02-28
US11471499B2 (en) 2022-10-18
PL3508209T3 (pl) 2022-06-13
EP3508209A1 (en) 2019-07-10
US10519426B2 (en) 2019-12-31
EP3041490A1 (en) 2016-07-13
US20160208222A1 (en) 2016-07-21
EA039404B1 (ru) 2022-01-24
HRP20220653T1 (hr) 2022-06-24
SMT202200214T1 (it) 2022-07-21
DK3508209T3 (da) 2022-05-30
CY1126790T1 (el) 2024-12-13
AU2014317215A8 (en) 2016-04-21
KR20160047570A (ko) 2016-05-02
CN106163532B (zh) 2019-12-31
HUE042382T2 (hu) 2019-06-28
KR102310692B1 (ko) 2021-10-12
EP4101457A1 (en) 2022-12-14
EP3508209B1 (en) 2022-03-09
JP6557234B2 (ja) 2019-08-07
HK1225643B (en) 2017-09-15
TW201606079A (zh) 2016-02-16
CA2922071A1 (en) 2015-03-12
JP6862500B2 (ja) 2021-04-21
ES2914577T3 (es) 2022-06-14
AU2014317215B2 (en) 2019-03-28
DK3041490T3 (en) 2019-03-04
TWI653334B (zh) 2019-03-11
MX2016002771A (es) 2016-09-06
TR201902073T4 (tr) 2019-03-21
PT3508209T (pt) 2022-05-27
LT3041490T (lt) 2019-02-25
AU2019204419A1 (en) 2019-07-11
JP2019193662A (ja) 2019-11-07
EP3041490B1 (en) 2018-11-14
US20200181581A1 (en) 2020-06-11
CN111944767A (zh) 2020-11-17
RS63291B1 (sr) 2022-06-30
MX2019010364A (es) 2019-10-07
CA2922071C (en) 2022-05-03
JP2016533749A (ja) 2016-11-04

Similar Documents

Publication Publication Date Title
MX2019010364A (es) Composiciones que presentan un virus de la enfermedad de newcastle atenuado y metodos de uso en el tratamiento de neoplasias.
CY1123404T1 (el) Αντι-girt αντισωματα
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
BR112014019049A2 (pt) adenovirus imunogênico
NZ711946A (en) Newcastle disease viruses and uses thereof
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
BR112014023005A2 (pt) diagnóstico rápido e tratamentos personalizados para acne
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
PH12014500793A1 (en) Recombinant non-pathogenic marek`s disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
CY1118118T1 (el) Συνεργατικες θεραπειες cannabidiol μαζι με υποθερμια για νευρο-προστασια
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
CY1122834T1 (el) Παραγωγα χλωρινης χρησιμα στη φωτοδυναμικη θεραπεια και τη διαγνωση
BR112017002809A2 (pt) métodos para tratar câncer cervical
EA201691314A1 (ru) Терапевтические способы и композиции
AU2013358947A8 (en) WT1 vaccine
NI201500151A (es) Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
MX2019005491A (es) Anticuerpo que enlaza especificamente a cd66c y uso del mismo.
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
MX2017014257A (es) Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t.
BR112016006210A2 (pt) terapia e vacina contra gripe
BR112016002317A8 (pt) Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
WO2014145498A3 (en) Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)

Legal Events

Date Code Title Description
FG Grant or registration